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Abstract
Although the exact etiology of Behçet’s disease (BD) remains unclear, a complex interaction between T cells and antigen-
presenting cells is known to be involved in the immunopathogenesis of BD. This study aimed to identify differentially 
expressed cell surface markers of peripheral blood mononuclear cells (PBMCs) in active and inactive stage of BD patients. 
PBMCs were isolated from six healthy controls, eight inactive BD patients and five active BD patients. Different cell 
phenotypes were analyzed by flow cytometry, serum cytokine levels were detected by ELISA and the morphological structure 
of polymorphonuclear neutrophils (PMN) was revealed by transmission electron microscope (TEM). The CD11b monocyte 
marker was slightly decreased in active BD patients (91.5±10.9%) compared with healthy controls (97.5±1.3%), but was not 
different compared to inactive BD patients (88.8±12.2%). The CD14 monocyte marker was significantly increased in active 
BD patients (28.9±18.7%, p=0.05) and inactivate BD patients (30.8±21.4%, p=0.08) compared to healthy controls (11.1±3.7%). 
However, CD16 (FcγRIIIA) was higher in inactive BD patients (93.9±2.4%) than active BD patients (85.3±14%), and CD32 
(FcγRII) was down-regulated in active BD patients (26.6±18.1%) compared to inactive BD patients (46.6±30.3%) and 
healthy controls (71.7±17.4%; p=0.002). Most surprisingly, the mannose receptor marker CD206 was highly expressed with 
significance in active BD patients (49.7±35.2%) compared to healthy controls (7.4±0.8%) (p=0.02) and inactive BD patients 
(4.7±3.1%) (p=0.007). In spite of the up-regulation of CD206 in active BD patients, interleukin-10 was markedly increased 
in the inactive state after improving medication than in the active state. All these findings show that differential surface 
expression of PBMCs between the inactive and active state of BD patients may influence changes of the disease state following 
treatment.
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Introduction
Behçet’s disease (BD) is a rare chronic inflammatory disease 
characterized by recurrent oral and/or genital aphthous 
ulcerations, uveitis and skin lesions. Clinical presentation 
of this disorder is multifaceted with severe chronic 
inflammation accompanied by articular, central nervous system, 
gastrointestinal, renal, urogenital, pulmonary and cardiovascular 
manifestations, all of which are associated with systemic 
vasculitis, a pivotal pathophysiological feature of BD [1-4]. The 
exact pathogenesis of BD remains unclear, but autoimmune 
and autoinflammatory reactions are important [5]. Initially 
in BD, infiltrated types of cells include CD4+ and CD8+ T cells, 
macrophages and dendritic cells, followed by neutrophils [6]. 
Th1/Th2-type immune responses have been investigated in 
cell-mediated immunity and inflammation in BD [7]. T helper 
(Th) 1 and Th17 predominant response has been observed in 
many studies in patients with BD; the response involves the 
increased production of cytokines including interleukin (IL)-2, 
IL-6, IL-8, IL-17, IL-12, IL-18, tumor necrosis factor-alpha (TNF-α), 
and interferon- gamma (IFN-gamma) [8,9].
CD11b is expressed on neutrophils, monocytes, natural killer (NK) 
cells and a subset of lymphocytes. CD11b has been implicated 
as having a central role in the migration of leukocytes from 
peripheral blood to the sites of inflammation [10,11], and is 
also involved in adhesion, chemotaxis and diapedesis during 
the process of host defense [12]. A previous study involving 
the examination of cultured monocytes from BD patients 
reported the significantly elevated expression of the CD11a, 
CD11b and CD18 adhesion molecules compared to cells from 
healthy subjects [13].
CD14 is a co-receptor of innate immunity. BD patients display 
up-regulated CD14 expression on monocytes and neutrophils 
and elevated serum soluble CD14 levels [14,15]. Very early 
activation confirmed by CD69 and CD14 response to heat 
shock protein 60 (HSP60) on peripheral blood mononuclear 
cells (PBMCs) of BD patients might be associated with an 
HSP60-induced innate activation through antigen presenting 
cells (APCs) [16]. CD16 is a Fc receptor (Fc RIII) that has been 
directly associated with neutrophil activation. Normally, CD14 
and CD16 are found together in secretory vesicles of neutrophils 
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and, when neutrophils are stimulated, CD14 and CD16 co-
migrate to the plasma membrane [17]. The intensity of CD16 
expression in patients with BD is equivocal [15,18]. In addition, 
FcγRII, namely CD32, has been detected on T cells, mast cells, 
monocytes, macrophages, and some epithelial and endothelial 
cell lineages. The primary function of CD32 appears to be 
antibody-mediated uptake of antigen and modulation of 
cellular activation and maturation events [19,20].
Macrophage mannose receptor (MMR), also known as 
CD206, is a scavenger receptor that is expressed primarily by 
tissue macrophages and lymphatic and hepatic endothelia 
in humans and mice [21,22]. MMR’s carbohydrate pattern 
recognition, potent capacity of endocytosis, and role in 
phagocytosis of microorganisms support a dual role in host 
defense and homeostasis [23]. In addition, CD206 has been 
identified in a variety of autoimmune and inflammatory 
diseases, such as systemic lupus erythematosus, ulcerative 
colitis, and Crohn’s disease [24,25]. However, the role of 
mannose receptor with other cell surface marker on PBMCs 
of active and inactive BD patients remain poorly understood 
in the host defense. In the present study, we investigated 
the pattern of cell-surface expression of CD11b, CD14, 
CD16, CD32 and CD206 on PBMCs of active and inactive 
BD patients before and after medications, respectively. We 
also attempted to characterize the serum IL-10 levels and 
cell surface expression during transformation of active to 
inactive form of BD. 
Materials and methods
Patients and healthy controls
The patient population consisted of 13 patients with BD 
who presented for the first time or were monitored at the 
Department of Dermatology, Yonsei University Hospital, 
Seoul, Korea. According to the International Study Group 
for BD criteria, the presence of any two of the following 
symptoms in addition to recurrent oral ulceration is diagnostic: 
genital ulceration, skin lesions, joint involvement, and ocular 
lesions. Presently, active BD patients had at least two of 
the BD symptoms and inactive BD patients who received 
anti-inflammatory medication were well controlled with no 
symptomatic states. Two of eight inactive BD patients were 
transferred from the active BD patient group. The control 
group consisted of six healthy volunteers (three women 
and three men; mean age, 29.6±3.5 years), the inactive BD 
patients consisted of eight (six women and two men; mean 
age, 48.4±15.0 years) and the active BD patients consisted 
of five (four women and one man; mean age, 30.0±8.6 years). 
Detailed clinical characteristics and therapeutic history of these 
patients are presented in Tables 1 and 2. Written informed 
consent was obtained from all participants prior to enrolling 
them into this study in accordance with the guidelines of the 
Declaration of Helsinki Principles. 
Cell preparation
PBMCs were isolated from heparinized venous blood by ACK 
lysing buffer. The cells were washed twice in phosphate-
buffered saline (PBS) and then resuspended in PBS. The cell 
suspensions were finally adjusted to a concentration of 1 x 
106 cells/ml and were processed further for cellular staining 
studies.
Flow cytometry
PBMCs were surface-stained with anti-human antibodies CD14 
(phycoerythrin (PE)-cy7), CD11b (fluorescein isothiocynate, 
FITC), CD16 (PE), CD32 (Allophycocyanin, APC) (eBiosciences, 
San Diego, CA, USA) and CD206 (Per-CP) (BD Biosciences 
Disease
condition
Patients Age Sex OU GU SL GI JI NEUR VAS OL Pathergy HLA-B51 ESR CRP
Active a 28 M + + + - - - - - - - 13 <0.01
b 31 F + - - - - - - + - + 65 <0.01
c 29 F + + + - + - - - - - 41 2.4
d 19 F + + + - + - - - - - 20 <1.00
e 43 F + + + - - - - - - + 50 2.33
Inactive a 28 M -- -- -- -- -- -- -- -- - - 2 <1.00
b 31 F -- -- -- -- -- -- -- -- - + 10 <1.00
f 59 F -- -- -- -- -- -- -- -- -- - 10 <1.00
g 64 F -- -- -- -- -- -- -- -- -- + 17 <1.00
h 53 F -- -- -- -- -- -- -- -- -- - 19 <1.00
i 45 M -- -- -- -- -- -- -- -- -- - 14 <1.00
j 39 F -- -- -- -- -- -- -- -- -- - 18 1.54
k 68 F -- -- -- -- -- -- -- -- -- - 2 <1.00
Table 1. Clinical and laboratory characteristics of inactive and active BD patients. 
M: male, F: female, OU: oral ulcers, GU: genital ulcers, SL: skin lesions, GI: gastrointestinal inflammation, JI: joint 
involvement, NEUR: neurological involvement, VAS: vasculitis, OL: ocular lesions.
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Pharmingen, San Diego, CA, USA) for 30 min at 4 °C in the 
dark. Isotype control antibodies were used to estimate the 
non-specific binding of target primary antibodies. Stained 
cells were analyzed by flow cytometry using a FACS Canto 
II (Becton Dickinson, San Jose, CA, USA) with ≥10,000 gated 
lymphocytes. 
Enzyme-linked immunosorbant assay (ELISA)
Serum was obtained from patients and healthy controls 
and analyzed using commercial ELISA kits for the detection 
of IL-10 (R&D Systems, Minneapolis, MN, USA) according to 
the manufacturer’s instructions. The mean and standard 
deviation were calculated using ELISA values determined for 
each well. The ELISA reader was Bio-Rad 170-6850 microplate 
reader (Bio-Rad, Hercules, CA, USA) and samples were read 
at a wavelength of 450 nm.
Transmission electron microscopy (TEM)
PBMCs were isolated from whole blood of healthy control, 
inactive and active BD patients and the morphological 
changes were observed using EM 902A transmission electron 
microscope (Zeiss, Oberkochen, Germany). In brief, cells were 
fixed using Karnovsky’s fixative solution (2% paraformaldehyde, 
2% glutaraldehyde, 0.5% calcium chloride in cacodylate 
buffer, pH 7.2) for 30 min, washed with cacodylate buffer, 
dehydrated in a series of graded ethanol and embedded in 
Epon mixture. After polymerization, ultrathin sections were 
cut using on Reichert Jung Ultracut S (Leica, Vienna, Austria), 
mounted on grids, stained with uranyl acetate and lead citrate 
and analyzed by TEM.  
Statistical analysis
Statistical analysis was performed using SPSS 11.0 software 
(SPSS, Chicago, IL, USA) and analyzed by Kruskal-Wallis Test 
and Bonferroni correction. A value of p<0.05 was considered 
statistically significant.
Results
Clinical and laboratory features of BD patients
All five active BD patients had severe manifestations consisting 
of oral ulcers with genital ulcers and skin lesions during the 
course of the disease. One patient (patient b) did not show 
genital ulcers and skin lesions, but did have ocular lesions. 
In addition, two patients (patient c and patient d) had joint 
complications. However, gastrointestinal infection, neurological 
involvement and vasculitis were not observed during the study 
period (Table 1). The laboratory tests performed were pathergy 
test, HLA-B51 detection, erythrocyte sedimentation rate 
(ESR) and C-reactive protein (CRP) level. Patients with active 
disease may generate an acute-phase response leading to 
a significantly raised ESR than inactive disease (37.8±21.39 
mm/h and 11.5±6.76 mm/h, p=0.007; respectively). Serum 
level of CRP was varied from <0.01 mg/dL to 2.4 mg/dL in 
active BD patients, and in inactive BD patients was from <1.0 
mg/dL to 1.54 mg/dL. Genetic factor HLA-B51 was positively 
detected in two active and two inactive BD patients. Finally, a 
pathergy test was performed; none of the active BD patients 
showed a positive result (Table 1). After blood sampling, active 
BD patients (Patient a and b) started treatment. Inactive BD 
patients were treated with colchicine, prednisolone, and 
azathioprine (n=1); colchicine, prednisolone, azathioprine, and 
cyclosporine (n=1); colchicine (n=3); colchicine and aspirin 
(n=2) and prednisolone (n=1). When the active BD patients 
were changed to inactive stage after medication (Table 2), 
blood was collected for laboratory analysis.
Differential surface expression on PBMCs of active and 
inactive BD patients
To identify differently expressed cell surface markers between 
active and inactive BD patients, PBMCs were isolated from 
healthy volunteers, active and inactive BD patients and 
labeled with antibodies and analyzed by flow cytometry. The 
CD11b monocyte marker was slightly decreased in active 
BD patients (91.5±10.9%) compared to healthy controls 
(97.5±1.3%), but was not different compared to inactive BD 
patients (88.8±12.2%). Monocyte marker CD14 was significantly 
increased in active BD patients (28.9±18.7%, p=0.05) and 
inactivate BD patients (30.8±21.4%, p=0.08) compared to 
healthy control (11.1±3.7%). Fc receptor contributes to the 
protective role of immune system by binding to pathogens 
Disease
condition
Patient Colchicine Prednisolone Azathioprine Aspirin Cyclosporine 
Inactive a* + + + - -
b* + + + - +
f + - - - -
g + - - - -
h + - - + -
i - + - - -
j + - - + -
k + - - - -
Table 2. Therapeutic history of inactive BD patients.
*, These two inactive patients were improved from active patients-a and b.
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[26]. CD16 (FcγRIIIA) is expressed on NK cells, macrophages 
and neutrophils. Presently, CD16 was higher in inactive BD 
patients (93.9±2.4%) than active BD patients (85.3±14%). CD32 
(FcγRII), which is important in regulating adaptive immunity 
[27], was down-regulated in active BD patients (26.6±18.1%) 
compared to inactive BD patients (46.6±30.3%; p=0.04) and 
healthy controls (71.7±17.4%, p=0.002). Most surprisingly, 
the mannose receptor marker CD206 was highly expressed 
with significance in active BD patients (49.7±35.2%) than in 
healthy controls (7.4±0.8%, p=0.02) and inactive BD patients 
(4.7±3.1%, p=0.007) (Figure 1). 
Characterization of CD11b+ subsets in active and 
inactive BD patients
CD11b is present in neutrophils, NK cells and macrophages, 
and is overexpressed in chronic obstructive pulmonary disease 
(COPD) [28]. CD14, the receptor for lipopolysaccharide binding 
protein, is expressed to a higher degree in blood monocytes 
than in tissue macrophages [29]. To determine whether the 
frequencies of co-expressed markers with CD11b+, CD14+, 
CD16+ or CD32+ cells were analyzed in PBMCs from healthy 
controls, active and inactive BD patients by flow cytometry. 
The frequencies of the CD11b+CD14+ cells in inactive and 
active BD patients were almost similar (27.7±4.1% and 
25.9±16.3%, respectively), but were higher than healthy 
controls (11.0±3.7%) (healthy vs inactive, p=0.03; healthy vs 
active, p=0.06). Although the frequencies of the CD11b+CD16+ 
cells were not significantly different among the groups (healthy 
85.5±4.7%, inactive 85.7±9.4% and active 82.2±15.9%), and 
the frequencies of the CD11b+CD32+ cells were significantly 
down-regulated in active BD patients (24.8±18%) (p=0.002) 
and inactive BD patients (47.8±27.8%) (p=0.04), as compared to 
healthy controls (70.6±18.2%). In addition, active BD patients 
showed down-regulation of CD11b+CD32+cells compared to 
inactive BD patients (Figure 2). 
Up-regulated expression of CD14+CD16+ subsets in 
active and inactive BD patients
CD14+ cells were increased in both inactive and active groups 
as compared to healthy controls (Figure 1). Similarly, double 
positive CD14+CD16+ cells were also significantly increased 
in inactive BD patients (36.1±22.4%, p=0.008) and active BD 
patient (22.9±17.6%, p=0.02) compared to healthy control 
(1.7±0.6%). CD14+CD16+ cells were reduced in active BD 
patients compared to inactive BD patients. Although the 
difference was not found significant, a similar pattern of surface 
expression was observed after analysis of CD14+CD32+ cells 
in inactive BD patients (18.0±13.3%) and active BD patients 
(10.4±4.4%) and healthy controls (7.9±1.3%) (Figure 3).
Increased expression of mannose receptor CD206 in 
active BD patients
To investigate the expression of mannose receptor in asso-
ciation with monocyte/macrophage subsets, we analyzed 
Figure 1. Surface expression on PBMCs of BD patients. PBMCs were isolated from healthy control (n=6), inactive (n=8) and 
active BD (n=5) patients. The surface expression of CD11b, CD14, CD16, CD32 and CD206 was analyzed by flow cytometry.
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CD11b+CD206+ and CD14+CD206+ cells in inactive and active 
BD patients. These populations were highly expressed in active 
BD patients with significance compared to healthy control 
(CD11b+CD206+ cells: 49.4±35.6% in active, 7.4±0.9% in healthy, 
p=0.02; and CD14+CD206+ cells: 14.6±9.6% in active, 5.6±1.4% 
in healthy, p=0.05) and inactive BD patients (CD11b+CD206+ 
cells: 49.4±35.6% in active, 4.4±3.1% in inactive, p=0.007; 
CD14+CD206+ cells, 14.6±9.6% in active, 4.4±2.9% in inactive, 
p=0.02) (Figure 4). 
Change of PBMC surface markers after improvement 
in two BD patients
Among the five active BD patients, two patients (patient a and 
b) were followed after treatment with colchicine, prednisolone 
and azathioprine in the absence or presence of cyclosporine 
(Table 2). When the symptoms changed to the inactive state, the 
surface expression on PBMCs was analyzed by flow cytometry. 
After improvement, the frequencies of CD14+ cells were highly 
increased in both patients at the inactive stage compared 
to the active stage (patient a from 29.8% to 53.0%; patient b 
from 7.8% to 44.4%). The frequencies of CD11b+ cells were 
slightly decreased at the inactive stage (81.9%) compared to 
the active stage (90.2%) in patient a, and were not different 
in patient b (inactive 96.4% vs active 96.7%). The frequencies 
of CD14+CD11b+ cells were also higher at the inactive stage 
(patient a 37.7%, patient b 42.4%) compared to the active stage 
(patient a 25.9%, patient b 7.4%) (Figure 5A). The frequencies 
of CD16+ cells were slightly increased at the inactive stage 
(patient a 95.8%, patient b 97.6%) compared to the active 
stage (patient a 90.9%, patient b 93.4%). The frequencies of 
CD16+CD11b+ cells were lower at the inactive stage (78.7%) 
compared to the active stage (86.6%) in patient a, but was 
similar in patient b (inactive 94.6% vs active 93.0%). In addition, 
double positive CD16+CD14+ cells were up-regulated at the 
Figure 3. The frequencies of CD14+CD16+ subsets were highly expressed in PBMCs of BD patients. The surface expression of  
CD14+CD16+ and CD14+CD32+ was analyzed by flow cytometry.
Figure 2. Expression of monocyte/macrophage marker CD11b+ subsets in BD patients. The frequencies of CD11b+CD14+, 
CD11b+CD16+ and CD11b+CD32+ cells were analyzed by flow cytometry in PBMCs from healthy control (n=6), inactive (n=8) and 
BD (n=5) patients.
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Figure 4. Frequencies of CD206 subsets are highly up-regulated in active BD patients. PBMCs were isolated from healthy 
control (n=6), inactive (n=8) and BD (n=5) patients. The surface expression of CD11b+CD206+ and CD14+CD206+ was 
analyzed by flow cytometry.
inactive stage (patient a 53.1%, patient b 43.3%) compared to 
the active stage (patient a 25.5%, patient b 3.8%) (Figure 5A).
In patient a, the frequency of single CD32+ cells was 
decreased at the inactive stage (active 34.0% vs inactive 
9.6%), but was increased in patient b (active 54.8% vs inactive 
85.8%). The frequency of double positive CD32+CD11b+ cells 
in patient a was also decreased at the inactive stage (active 
29.9% vs inactive 9.2%), but in patient b, the frequency of 
CD32+CD11b+ cells was increased (active 53.7% vs inactive 
84.7%). In addition, the frequency of CD32+CD14+ cells was 
decreased at the inactive stage (active 17.8% vs inactive 9.6%) 
in patient a, but was increased in patient b (active 6.0% vs 
inactive 38.1%). The frequencies of CD32+, CD32+CD11b+, and 
CD32+CD14+ cells showed opposite pattern of result between 
patient a and b (Figure 5B). 
The frequencies of CD206+ cells were highly up-regulated in 
the active stage (patient a 67%, patient b 68.1%) compared to 
the inactive stage (patient a 6%, patient b 2.5%). Furthermore, 
the frequencies of CD206+CD11b+ and CD206+CD14+cells 
were also increased at the active stage (patient a 65.8% and 
28.4%, respectively; patient b 67.9% and 7.3%, respectively) 
compared to the inactive stage (patient a 5.9% and 5.9%, 
respectively; patient b 2.4% and 2.5%, respectively) (Figure 5C).
Variations in the induction of anti-inflammatory cytokine 
IL-10 after improvement of BD patients
Serum was collected from BD patients a and b in their active 
and inactive stages. The anti-inflammatory cytokine IL-10 
level was evaluated by ELISA. In patient b, the IL-10 level 
was markedly induced in the inactive stage (33.25 pg/ml) 
compared to the active stage (5.41 pg/ml). In patient a, IL-
10 was slightly increased in the inactive stage (11.39 pg/ml) 
compared to the active stage (3.36 pg/ml) (Figure 6). 
Observation of intracellular morphology of 
polymorphonuclear neutrophils (PMNs) by TEM
PMNs contain two types of chemically distinct cytoplasmic 
granules, which appear at different stages of maturation. The 
larger and dense azurophilic granule (or primary granule) 
is formed during the promyelocyte stage and contains 
myeloperoxidase in addition to numerous lysosomal enzymes, 
neutral proteases, glycosaminoglycans, cationic bactericidal 
proteins and lysozyme. The specific granule (or secondary 
granule) is formed during the myelocyte stage. Mature PMNs 
contain both types of granules: 33% azurophilic and 67% 
specific granules [30]. To observe the intracellular changes 
occurred at different stages of BD, we isolated PBMCs from 
whole blood of healthy controls, and inactive and active BD 
patients, and observed with TEM. In this study, PBMCs had 
a normal structural appearance in the healthy control and 
inactive stage groups. In contrast, huge azurophilic granules 
were aggregated in the cytoplasm of the neutrophils in active 
BD patients (Figure 7).
Discussion 
The exact etiology and immunopathological features of BD 
are not clear yet. But, immunological properties may play a 
role in disease sequela. The frequencies of CD11b+ cells in 
neutrophils are higher in BD patients than in healthy controls 
[31]. CD8+CD11b+ cells are reportedly increased in BD patients 
compared to healthy controls [32], and thalidomide treatment 
down-regulates CD8+CD11b+ cells [18]. In another study, 
CD11b was significantly high in active compared to inactive 
BD patients or healthy control [33]. However, our data showed 
lower frequencies of CD11b in BD patients than in healthy 
controls, although the difference was not significantly different. 
The prior study reported on BD patients with ocular lesion, 
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Figure 5. The frequencies of surface expression were changed in after improvement of 
two BD patients. PBMCs were isolated from two BD patients (patient a and b) before 
and after treatment with colchicine, prednisolone and azathioprine with or without 
cyclosporine. A~ C. The surface expression of CD11b, CD14, CD16, CD32, CD206 and 
their subsets was analyzed by flow cytometry.
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but in our five patients, only one had ocular BD. Therefore, the 
difference of CD11b expression pattern to the study of Ahn 
et al., could be explained by different symptom composition.
Presently, the CD11b blood monocyte marker was lower 
in active BD patients than healthy controls, but the CD14 
monocyte marker was highly expressed in inactive and active 
BD patients compared to healthy controls. In a previous study, 
Eksioglu-Demiralp et al., reported similar expression pattern 
of CD14 in BD [15]. Houman et al., reported no significant 
differences in the proportion of CD11b+CD14+ cells between 
the active and inactive stages, but CD11b+CD14+ cells were 
highly expressed compared to healthy controls [34]. Our data 
also demonstrated a similar expression pattern as reported 
by Houman. CD11b+CD32+ cells were significantly down-
regulated in active and inactive BD patients compared to 
healthy controls, whereas no significant differences were 
evident in the proportion of CD11b+CD16+ cells between 
healthy controls and both active and inactive BD patients. 
These results indicate that among the CD11b+ subsets, 
CD11b+CD14+ and CD11b+CD32+ cells are important in the 
induction of BD, but are unrelated with symptoms. The 
CD11b+CD14+ and CD11b+CD32+ subsets were not significantly 
different between active and inactive BD patients. The CD14+ 
subsets and CD32+ subsets in CD11b+ population displayed 
a reciprocal negative regulation according to the inhibition 
of CD32+ macrophage activation from CD14+ monocytes. 
CD14 is a membrane-bound protein that is expressed in 
monocytes, macrophages, polymorphonuclear neutrophils 
[35] and dendritic cells [36]. CD32 is a marker of indication in 
monocyte activation [37] and one of the Fc-IgG receptors [38]. 
Fc-IgG receptors contribute to the pathogenesis of immune 
complex- and auto-antibody mediated diseases such as 
vasculitis, rheumatoid arthritis or autoimmune neutropenia 
[38,39]. CD32 also plays an essential role in the removal of 
antigen-antibody complexes from the circulation and cell-to-
cell interactions mediating antibody-dependent cell-mediated 
cytotoxicity. CD14+CD16+ monocytes are reportedly increased 
in sepsis patients with severe infection [40] and efficiently 
produce the pro-inflammatory cytokine TNF-α, while they 
produce no or little of the anti-inflammatory cytokine IL-
10 [41]. Our results also showed significantly up-regulated 
frequencies of CD14+CD16+ subsets in BD patients (Figure 3) 
and markedly elevated IL-10 levels in improved inactive BD 
patients compared to active BD patients (Figure 6). In BD 
patients, the frequencies of CD14+CD16+ cells were higher 
in the inactive stage than in the active stage, although the 
difference was not statistically significant. In addition, a similar 
pattern was also observed in CD14+CD32+ cells.
A recent study reported that anti-TNF-α monoclonal 
antibodies (Infliximab and Adulimumab) are effective in 
treating patients with Crohn’s disease (CD), which might 
contribute to the resolution of inflammation [42,43]. In 
addition, antibody against TNF-α induced the formation of 
a new population of macrophages in a Fc region-dependent 
Figure 6. IL-10 serum level is increased after improvement 
of BD patients. Serum was collected from two BD patients 
(patient a and b) in their active and inactive stages and 
evaluated IL-10 level by ELISA.
Figure 7. Distinct difference in the intracellular morphology 
of polymorphonuclear neutrophils of BD patients. PBMCs 
were isolated from whole blood of healthy control, inactive 
and active BD patients and the morphological changes were 
observed using transmission electron microscopy. The inlets 
of the microphotographs indicate the azurophilic granules 
in the cytoplasm of the neutrophil. Scale bar indicates the 
magnification for an individual photograph.
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manner; these macrophages had an immunosuppressive 
phenotype because they inhibit the proliferation of activated 
T cells, produce anti-inflammatory cytokines, and express the 
macrophage marker CD206 [44]. However, in this study, a clear 
and significant increase was observed in the frequencies of 
CD206+, CD11b+CD206+ cells and CD14+CD206+ cells in active 
BD patients compared to the inactive stage. Significant down-
regulation was also observed in each individual inactive BD 
patient, which was recovered after receiving a combined 
therapy. Although patients with inflammatory bowel disease 
responding to infliximab displayed increased numbers of 
CD206+ cells [45], our data show that combination therapy 
with colchicine, prednisolone and azathioprine with or without 
cyclosporine improved BD symptoms with the reduction 
of CD206 macrophages. Although there have been several 
reports on mannose binding lectin polymorphism in BD 
[46-48], until now there was no report on mannose receptor 
related one. Here, we report that mannose receptor CD206 
is related to BD, and specifically the presence of symptoms 
in active BD patients.
Although no differences were evident in the frequencies 
of CD11b+CD14+ cells between the active and inactive stages 
(Figure 2), after improvement with the combination therapy 
the frequencies of CD11b+CD14+ cells were markedly increased 
in the improved stage in both patient groups.
In a previous study, the frequencies of CD14+CD16+ 
monocytes were lower in rheumatoid arthritis patients 
compared to normal subjects [49]. In this study, the frequencies 
of CD14+CD16+ were higher in BD patients compared to normal 
subjects (Figure 3), and treatment up-regulated CD14+CD16+ 
cells in both patients. No effect of cyclosporine related to the 
frequencies of CD16+CD14+ cells after improvement was evident 
(Figure 5A). An opposite pattern of expression was observed in 
CD32+ subsets between both patients after improvement, in 
which the frequencies of CD32+CD11b+ and CD32+CD14+ cells 
were lower in the inactive stage of patient a, but was higher 
in patient b. These data show that a complicated immune 
response regulated the improvement of BD patients, which 
may vary with their choice of drugs or may be related to the 
ocular involvement.
PMNs are the most abundant white blood cells in the 
peripheral blood of humans, and are associated with the 
host defense. They are known as the “first line defense”, 
particularly against bacterial infections [50]. Because of their 
cytotoxic and proteolytic potential, PMNs can also attack and 
damage the surrounding tissue, and thus can contribute to 
destructive inflammatory processes [51]. There is increasing 
evidence that PMNs are not only effector cells of the acute 
inflammatory reaction, but that they also participate in chronic 
inflammatory diseases, such as rheumatoid arthritis, primary 
vasculitis and inflammatory bowel disease [52,53]. In this 
study, we found a distinct morphological difference in PMNs 
of active BD patients, in which huge azurophilic granules were 
aggregated in the cytoplasm of the neutrophil in active BD 
patients. In contrast, in inactive BD patients, the granules had 
disappeared or were decreased. Koga et al., also reported 
that the quantity of intracytoplasmic granules in blood 
monocytes and macrophages were correlated with disease 
severity in Kawasaki disease [54]. These intracytoplasmic 
granules store inflammatory mediators and are considered 
structural markers of inflammation [55], therefore, having a 
role in pathology of inflammatory diseases. 
In conclusion, a comparative analysis of different expression 
of monocyte/ macrophage markers revealed a considerable 
variation in phenotypes between active and inactive stage of 
BD patients. The CD14 monocyte marker was highly expressed 
in active and inactive BD patients compared to healthy controls, 
but another monocyte marker, CD11b, was decreased in 
active BD patients compared to healthy control. Moreover, 
their subsets were also expressed differently in active BD 
patients compared to healthy control. Mannose receptor 
(CD206) and its subset were consistently highly expressed 
in active BD patients compared to inactive BD patients. 
Furthermore, the recovery state of the BD patients showed 
down-regulated frequencies of CD206 in both patients with 
or without ocular symptoms after treatment with colchicine, 
prednisolone and azathioprine with or without cyclosporine. 
In accordance with CD206, anti-inflammatory cytokine IL-10 
was highly up-regulated in improved state with combined 
drugs with or without cyclosporine. Taken together, the data 
reveal that the peripheral inflammatory environment during 
active stage of BD might be dominated by monocytes, which 
depend on the expression of surface markers representing 
polarized phenotypes. In the future, we shall perform the 
large scale study to overcome this limited cases.
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